Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 17, 2026, 5:48 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 590006 | NSE: AMRUTANJAN

Amrutanjan Health Care Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 17, 2026, 5:48 pm

Market Cap 1,766 Cr.
Current Price 610
Intrinsic Value₹463.65
High / Low 791/544
Stock P/E30.5
Book Value 118
Dividend Yield0.75 %
ROCE22.4 %
ROE16.5 %
Face Value 1.00
PEG Ratio-9.74

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Amrutanjan Health Care Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 123 Cr. 97.7 137/84.325.5 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.21 Cr. 1.68 4.02/1.68 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 3,513 Cr. 319 479/19273.5 24.30.21 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 28.2 Cr. 38.0 79.8/37.2 10.60.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 87.8 Cr. 59.9 59.9/17.0351 6.930.00 %13.5 %11.0 % 10.0
Industry Average20,203.79 Cr1,104.9657.48201.330.37%16.29%15.20%6.10

All Competitor Stocks of Amrutanjan Health Care Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 9810078991171278411012313594118141
Expenses 858771929511180969911886101116
Operating Profit 1213772216414231881725
OPM % 12%13%9%7%18%13%4%12%19%13%9%14%18%
Other Income 4544454445443
Interest 0000000000000
Depreciation 1112222222222
Profit before tax 15169924206162621111926
Tax % 26%23%26%26%26%30%27%26%26%27%26%27%26%
Net Profit 1113771714512191581419
EPS in Rs 3.664.342.402.376.044.721.604.086.665.252.874.836.73

Last Updated: February 6, 2026, 6:17 pm

Below is a detailed analysis of the quarterly data for Amrutanjan Health Care Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 118.00 Cr. (Sep 2025) to 141.00 Cr., marking an increase of 23.00 Cr..
  • For Expenses, as of Dec 2025, the value is 116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Sep 2025) to 116.00 Cr., marking an increase of 15.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Sep 2025) to 25.00 Cr., marking an increase of 8.00 Cr..
  • For OPM %, as of Dec 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Sep 2025) to 18.00%, marking an increase of 4.00%.
  • For Other Income, as of Dec 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Sep 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
  • For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 2.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Sep 2025) to 26.00 Cr., marking an increase of 7.00 Cr..
  • For Tax %, as of Dec 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Sep 2025) to 26.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Dec 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Sep 2025) to 19.00 Cr., marking an increase of 5.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 6.73. The value appears strong and on an upward trend. It has increased from 4.83 (Sep 2025) to 6.73, marking an increase of 1.90.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 5:40 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 131154174207220253261333406380421452470
Expenses 108130143178192222231258326335369394404
Operating Profit 23253229283131758045525866
OPM % 18%16%18%14%13%12%12%22%20%12%12%13%14%
Other Income 3567878111515161818
Interest 2100000110000
Depreciation 3232334445676
Profit before tax 21263534333534829154626977
Tax % 32%35%35%35%39%29%27%25%26%26%27%26%
Net Profit 15172222202525616740455157
EPS in Rs 4.975.867.687.476.848.398.5820.9322.9913.6315.5517.5819.61
Dividend Payout % 32%30%25%26%22%26%24%20%20%34%30%26%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)13.33%29.41%0.00%-9.09%25.00%0.00%144.00%9.84%-40.30%12.50%13.33%
Change in YoY Net Profit Growth (%)0.00%16.08%-29.41%-9.09%34.09%-25.00%144.00%-134.16%-50.13%52.80%0.83%

Amrutanjan Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:11%
5 Years:12%
3 Years:4%
TTM:8%
Compounded Profit Growth
10 Years:11%
5 Years:15%
3 Years:-9%
TTM:28%
Stock Price CAGR
10 Years:14%
5 Years:11%
3 Years:-1%
1 Year:-9%
Return on Equity
10 Years:19%
5 Years:20%
3 Years:15%
Last Year:17%

Last Updated: September 4, 2025, 11:10 pm

Balance Sheet

Last Updated: December 10, 2025, 2:21 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 3333333333333
Reserves 94102118113126143156213262288286324339
Borrowings 6002002111222
Other Liabilities 22252834384244578470779388
Total Liabilities 124130149152166188205274350362367421432
Fixed Assets 15132227282626232849504949
CWIP 1411000217121626
Investments 141410108181818135000
Other Assets 95100116115131144161232291307315356357
Total Assets 124130149152166188205274350362367421432

Below is a detailed analysis of the balance sheet data for Amrutanjan Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
  • For Reserves, as of Sep 2025, the value is 339.00 Cr.. The value appears strong and on an upward trend. It has increased from 324.00 Cr. (Mar 2025) to 339.00 Cr., marking an increase of 15.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). It has decreased from 93.00 Cr. (Mar 2025) to 88.00 Cr., marking a decrease of 5.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 432.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 421.00 Cr. (Mar 2025) to 432.00 Cr., marking an increase of 11.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 49.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 49.00 Cr..
  • For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
  • For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 356.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 1.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 432.00 Cr.. The value appears strong and on an upward trend. It has increased from 421.00 Cr. (Mar 2025) to 432.00 Cr., marking an increase of 11.00 Cr..

Notably, the Reserves (339.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +18192181921189152202851
Cash from Investing Activity +16-51-0-8-11-14-88-36-219-31
Cash from Financing Activity +-14-12-11-5-9-7-12-7-17-15-48-13
Net Cash Flow20212323-7-4-13-16

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow17.0025.0032.0027.0028.0031.0029.0074.0079.0044.0050.0056.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 666255514647371934324245
Inventory Days 454444444045744553585045
Days Payable 44465111010292981061229596113
Cash Conversion Cycle 676148-15-16013-41-35-6-5-23
Working Capital Days 39424576263070289211717399
ROCE %24%26%29%28%25%25%23%44%38%19%21%22%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters50.02%50.03%50.03%50.59%50.59%50.59%50.58%46.52%46.52%46.52%46.52%46.52%
FIIs0.76%0.68%0.69%0.75%0.80%1.38%1.55%2.34%2.30%2.30%2.41%2.38%
DIIs6.39%7.18%7.22%7.10%7.24%7.29%7.32%10.60%11.13%11.41%12.70%12.90%
Public42.65%41.93%41.87%41.39%41.19%40.66%40.47%40.50%40.01%39.75%38.34%38.16%
Others0.18%0.18%0.18%0.18%0.18%0.07%0.07%0.04%0.04%0.04%0.04%0.04%
No. of Shareholders72,10469,94771,42872,00268,40462,66457,16954,53653,85651,67449,43147,954

Shareholding Pattern Chart

No. of Shareholders

Amrutanjan Health Care Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
DSP Small Cap Fund 1,466,269 0.58 98.031,466,2692025-04-22 15:57:000%
ICICI Prudential FMCG Fund 713,715 2.5 47.72N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 17Mar 16Mar 15Mar 14Mar 13
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 14.4714.0810.318.516.92
Diluted EPS (Rs.) 14.4714.0810.318.516.92
Cash EPS (Rs.) 16.4316.3712.5110.989.47
Book Value[Excl.RevalReserv]/Share (Rs.) 86.2274.4064.9761.0656.29
Book Value[Incl.RevalReserv]/Share (Rs.) 86.2274.4064.9761.0656.29
Revenue From Operations / Share (Rs.) 153.25127.77113.9796.9794.18
PBDIT / Share (Rs.) 23.1624.9519.3216.9314.83
PBIT / Share (Rs.) 21.2022.6617.1314.4712.28
PBT / Share (Rs.) 22.7522.3616.6413.2610.59
Net Profit / Share (Rs.) 14.4714.0810.318.516.92
NP After MI And SOA / Share (Rs.) 14.4714.0810.318.516.92
PBDIT Margin (%) 15.1119.5216.9517.4615.75
PBIT Margin (%) 13.8317.7315.0214.9213.04
PBT Margin (%) 14.8417.5014.6013.6711.24
Net Profit Margin (%) 9.4311.019.048.787.34
NP After MI And SOA Margin (%) 9.4311.019.048.787.34
Return on Networth / Equity (%) 16.7718.9215.8713.9412.29
Return on Capital Employeed (%) 23.8729.4525.5222.7320.83
Return On Assets (%) 13.0714.6512.1610.348.14
Total Debt / Equity (X) 0.010.020.020.080.18
Asset Turnover Ratio (%) 1.481.351.301.121.00
Current Ratio (X) 3.463.593.202.871.67
Quick Ratio (X) 3.153.272.872.551.40
Inventory Turnover Ratio (X) 7.677.096.936.065.44
Dividend Payout Ratio (NP) (%) 0.0027.3433.9337.5843.33
Dividend Payout Ratio (CP) (%) 0.0023.5227.9729.1431.67
Earning Retention Ratio (%) 0.0072.6666.0762.4256.67
Cash Earning Retention Ratio (%) 0.0076.4872.0370.8668.33
Interest Coverage Ratio (X) 78.7283.4739.7214.018.75
Interest Coverage Ratio (Post Tax) (X) 43.9148.1022.208.055.08
Enterprise Value (Cr.) 817.64564.15663.81156.21169.76
EV / Net Operating Revenue (X) 3.653.023.991.101.23
EV / EBITDA (X) 24.1615.4723.516.317.83
MarketCap / Net Operating Revenue (X) 3.853.274.201.291.23
Retention Ratios (%) 0.0072.6566.0662.4156.66
Price / BV (X) 6.855.617.362.062.06
Price / Net Operating Revenue (X) 3.853.274.201.291.23
EarningsYield 0.020.030.020.060.05

After reviewing the key financial ratios for Amrutanjan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 17, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
  • For Diluted EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
  • For Cash EPS (Rs.), as of Mar 17, the value is 16.43. This value is within the healthy range. It has increased from 16.37 (Mar 16) to 16.43, marking an increase of 0.06.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
  • For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 153.25. It has increased from 127.77 (Mar 16) to 153.25, marking an increase of 25.48.
  • For PBDIT / Share (Rs.), as of Mar 17, the value is 23.16. This value is within the healthy range. It has decreased from 24.95 (Mar 16) to 23.16, marking a decrease of 1.79.
  • For PBIT / Share (Rs.), as of Mar 17, the value is 21.20. This value is within the healthy range. It has decreased from 22.66 (Mar 16) to 21.20, marking a decrease of 1.46.
  • For PBT / Share (Rs.), as of Mar 17, the value is 22.75. This value is within the healthy range. It has increased from 22.36 (Mar 16) to 22.75, marking an increase of 0.39.
  • For Net Profit / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
  • For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
  • For PBDIT Margin (%), as of Mar 17, the value is 15.11. This value is within the healthy range. It has decreased from 19.52 (Mar 16) to 15.11, marking a decrease of 4.41.
  • For PBIT Margin (%), as of Mar 17, the value is 13.83. This value is within the healthy range. It has decreased from 17.73 (Mar 16) to 13.83, marking a decrease of 3.90.
  • For PBT Margin (%), as of Mar 17, the value is 14.84. This value is within the healthy range. It has decreased from 17.50 (Mar 16) to 14.84, marking a decrease of 2.66.
  • For Net Profit Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
  • For NP After MI And SOA Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
  • For Return on Networth / Equity (%), as of Mar 17, the value is 16.77. This value is within the healthy range. It has decreased from 18.92 (Mar 16) to 16.77, marking a decrease of 2.15.
  • For Return on Capital Employeed (%), as of Mar 17, the value is 23.87. This value is within the healthy range. It has decreased from 29.45 (Mar 16) to 23.87, marking a decrease of 5.58.
  • For Return On Assets (%), as of Mar 17, the value is 13.07. This value is within the healthy range. It has decreased from 14.65 (Mar 16) to 13.07, marking a decrease of 1.58.
  • For Total Debt / Equity (X), as of Mar 17, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 16) to 0.01, marking a decrease of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 17, the value is 1.48. It has increased from 1.35 (Mar 16) to 1.48, marking an increase of 0.13.
  • For Current Ratio (X), as of Mar 17, the value is 3.46. This value exceeds the healthy maximum of 3. It has decreased from 3.59 (Mar 16) to 3.46, marking a decrease of 0.13.
  • For Quick Ratio (X), as of Mar 17, the value is 3.15. This value exceeds the healthy maximum of 2. It has decreased from 3.27 (Mar 16) to 3.15, marking a decrease of 0.12.
  • For Inventory Turnover Ratio (X), as of Mar 17, the value is 7.67. This value is within the healthy range. It has increased from 7.09 (Mar 16) to 7.67, marking an increase of 0.58.
  • For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 27.34 (Mar 16) to 0.00, marking a decrease of 27.34.
  • For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.52 (Mar 16) to 0.00, marking a decrease of 23.52.
  • For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 72.66 (Mar 16) to 0.00, marking a decrease of 72.66.
  • For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.48 (Mar 16) to 0.00, marking a decrease of 76.48.
  • For Interest Coverage Ratio (X), as of Mar 17, the value is 78.72. This value is within the healthy range. It has decreased from 83.47 (Mar 16) to 78.72, marking a decrease of 4.75.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 43.91. This value is within the healthy range. It has decreased from 48.10 (Mar 16) to 43.91, marking a decrease of 4.19.
  • For Enterprise Value (Cr.), as of Mar 17, the value is 817.64. It has increased from 564.15 (Mar 16) to 817.64, marking an increase of 253.49.
  • For EV / Net Operating Revenue (X), as of Mar 17, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 3.02 (Mar 16) to 3.65, marking an increase of 0.63.
  • For EV / EBITDA (X), as of Mar 17, the value is 24.16. This value exceeds the healthy maximum of 15. It has increased from 15.47 (Mar 16) to 24.16, marking an increase of 8.69.
  • For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
  • For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 72.65 (Mar 16) to 0.00, marking a decrease of 72.65.
  • For Price / BV (X), as of Mar 17, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 5.61 (Mar 16) to 6.85, marking an increase of 1.24.
  • For Price / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
  • For EarningsYield, as of Mar 17, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 16) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Amrutanjan Health Care Ltd as of February 17, 2026 is: ₹478.63

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 17, 2026, Amrutanjan Health Care Ltd is Overvalued by 21.54% compared to the current share price ₹610.00

Intrinsic Value of Amrutanjan Health Care Ltd as of February 17, 2026 is: ₹463.65

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 17, 2026, Amrutanjan Health Care Ltd is Overvalued by 23.99% compared to the current share price ₹610.00

Last 5 Year EPS CAGR: -3.13%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 27.00%, which is a positive sign.
  2. The company has higher reserves (197.23 cr) compared to borrowings (1.46 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (297.08 cr) and profit (50.23 cr) over the years.
  1. The stock has a high average Working Capital Days of 69.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 4.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amrutanjan Health Care Ltd:
    1. Net Profit Margin: 9.43%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 23.87% (Industry Average ROCE: 16.29%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 16.77% (Industry Average ROE: 15.2%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 43.91
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 3.15
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 30.5 (Industry average Stock P/E: 57.48)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.01
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Amrutanjan Health Care Ltd. is a Public Limited Listed company incorporated on 09/09/1936 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24231TN1936PLC000017 and registration number is 000017. Currently Company is involved in the business activities of Manufacture of `ayurvedic' or `unani' pharmaceutical preparation. Company's Total Operating Revenue is Rs. 451.82 Cr. and Equity Capital is Rs. 2.89 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsNo.103 (Old No.42-45), Chennai (Madras) Tamil Nadu 600004Contact not found
Management
NamePosition Held
Mr. S Sambhu PrasadChairman & Managing Director
Mr. G RaghavanNon Executive Director
Ms. Ramaa Prabhakar ArikirevulaNon Executive Director
Ms. Meenalochani RaghunathanInd. Non-Executive Director
Mr. Raja VenkataramanInd. Non-Executive Director
Mr. S MuralidharanInd. Non-Executive Director
Mr. V NagarajInd. Non-Executive Director

FAQ

What is the intrinsic value of Amrutanjan Health Care Ltd?

Amrutanjan Health Care Ltd's intrinsic value (as of 17 February 2026) is ₹463.65 which is 23.99% lower the current market price of ₹610.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,766 Cr. market cap, FY2025-2026 high/low of ₹791/544, reserves of ₹339 Cr, and liabilities of ₹432 Cr.

What is the Market Cap of Amrutanjan Health Care Ltd?

The Market Cap of Amrutanjan Health Care Ltd is 1,766 Cr..

What is the current Stock Price of Amrutanjan Health Care Ltd as on 17 February 2026?

The current stock price of Amrutanjan Health Care Ltd as on 17 February 2026 is ₹610.

What is the High / Low of Amrutanjan Health Care Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Amrutanjan Health Care Ltd stocks is ₹791/544.

What is the Stock P/E of Amrutanjan Health Care Ltd?

The Stock P/E of Amrutanjan Health Care Ltd is 30.5.

What is the Book Value of Amrutanjan Health Care Ltd?

The Book Value of Amrutanjan Health Care Ltd is 118.

What is the Dividend Yield of Amrutanjan Health Care Ltd?

The Dividend Yield of Amrutanjan Health Care Ltd is 0.75 %.

What is the ROCE of Amrutanjan Health Care Ltd?

The ROCE of Amrutanjan Health Care Ltd is 22.4 %.

What is the ROE of Amrutanjan Health Care Ltd?

The ROE of Amrutanjan Health Care Ltd is 16.5 %.

What is the Face Value of Amrutanjan Health Care Ltd?

The Face Value of Amrutanjan Health Care Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Amrutanjan Health Care Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports